122 related articles for article (PubMed ID: 15198482)
1. Ultrasound evaluation of valsartan therapy for renal cortical perfusion.
Kishimoto N; Mori Y; Nishiue T; Nose A; Kijima Y; Tokoro T; Yamahara H; Okigaki M; Kosaki A; Iwasaka T
Hypertens Res; 2004 May; 27(5):345-9. PubMed ID: 15198482
[TBL] [Abstract][Full Text] [Related]
2. Renal blood flow measurement with contrast-enhanced harmonic ultrasonography: evaluation of dopamine-induced changes in renal cortical perfusion in humans.
Kishimoto N; Mori Y; Nishiue T; Shibasaki Y; Iba O; Nose A; Uchiyama-Tanaka Y; Masaki H; Matsubara H; Iwasaka T
Clin Nephrol; 2003 Jun; 59(6):423-8. PubMed ID: 12834173
[TBL] [Abstract][Full Text] [Related]
3. Interactions between nitric oxide and angiotensin II on renal cortical and papillary blood flow.
Madrid MI; García-Salom M; Tornel J; de Gasparo M; Fenoy FJ
Hypertension; 1997 Nov; 30(5):1175-82. PubMed ID: 9369273
[TBL] [Abstract][Full Text] [Related]
4. Haemodynamic effects of valsartan in acute renal ischaemia/reperfusion injury.
Lopau K; Hefner L; Bender G; Heidbreder E; Wanner C
Nephrol Dial Transplant; 2001 Aug; 16(8):1592-7. PubMed ID: 11477160
[TBL] [Abstract][Full Text] [Related]
5. Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects.
Fricker AF; Nussberger J; Meilenbrock S; Brunner HR; Burnier M
Kidney Int; 1998 Dec; 54(6):2089-97. PubMed ID: 9853274
[TBL] [Abstract][Full Text] [Related]
6. Evidence for abundant presence of chymase-positive mast cells in the kidneys of patients with immunoglobulin A nephropathy: effect of combination therapy with prednisolone and angiotensin II receptor blocker valsartan.
Konishi Y; Morikawa T; Okada N; Maeda I; Kitabayashi C; Yoshioka K; Okumura M; Nishiyama A; Ueda M; Takai S; Miyazaki M; Imanishi M
Hypertens Res; 2008 Aug; 31(8):1517-24. PubMed ID: 18971525
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension.
Delles C; Klingbeil AU; Schneider MP; Handrock R; Weidinger G; Schmieder RE
Am J Hypertens; 2003 Dec; 16(12):1030-5. PubMed ID: 14643577
[TBL] [Abstract][Full Text] [Related]
8. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
Watanabe S; Okura T; Kurata M; Irita J; Manabe S; Miyoshi K; Fukuoka T; Gotoh A; Uchida K; Higaki J
Clin Exp Hypertens; 2006 Jul; 28(5):451-61. PubMed ID: 16820342
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
Hayashi N; Yamamoto S; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):620-5. PubMed ID: 9205775
[TBL] [Abstract][Full Text] [Related]
10. Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
Siragy HM; El-Kersh MA; De Gasparo M; Webb RL; Carey RM
J Hypertens; 2002 Jun; 20(6):1157-63. PubMed ID: 12023686
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.
Okura T; Watanabe S; Kurata M; Koresawa M; Irita J; Enomoto D; Jotoku M; Miyoshi K; Fukuoka T; Higaki J
Clin Exp Hypertens; 2008 Jul; 30(5):415-22. PubMed ID: 18633763
[TBL] [Abstract][Full Text] [Related]
12. Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging.
Declèves AE; Rychak JJ; Smith DJ; Sharma K
Am J Physiol Renal Physiol; 2013 Nov; 305(9):F1343-51. PubMed ID: 24049144
[TBL] [Abstract][Full Text] [Related]
13. Renal perfusion evaluation with contrast-enhanced ultrasonography.
Schneider AG; Hofmann L; Wuerzner G; Glatz N; Maillard M; Meuwly JY; Eggimann P; Burnier M; Vogt B
Nephrol Dial Transplant; 2012 Feb; 27(2):674-81. PubMed ID: 21690200
[TBL] [Abstract][Full Text] [Related]
14. Effect of interactions between nitric oxide and angiotensin II on pressure diuresis and natriuresis.
Madrid MI; García-Salom M; Tornel J; De Gasparo M; Fenoy FJ
Am J Physiol; 1997 Nov; 273(5):R1676-82. PubMed ID: 9374809
[TBL] [Abstract][Full Text] [Related]
15. A new method for evaluation of split renal cortical blood flow with contrast echography.
Hosotani Y; Takahashi N; Kiyomoto H; Ohmori K; Hitomi H; Fujioka H; Aki Y; Fukunaga M; Yuasa S; Mizushige K; Kohno M
Hypertens Res; 2002 Jan; 25(1):77-83. PubMed ID: 11924730
[TBL] [Abstract][Full Text] [Related]
16. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.
Komers R; Cooper ME
Am J Physiol; 1995 Apr; 268(4 Pt 2):F588-94. PubMed ID: 7733315
[TBL] [Abstract][Full Text] [Related]
17. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
Rehman A; Rahman AR; Rasool AH
J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
[TBL] [Abstract][Full Text] [Related]
18. Contribution of bradykinin B2 receptors to the inhibition by valsartan of systemic and renal effects of exogenous angiotensin II in salt-repleted humans.
Biggi A; Musiari L; Iori M; De Iaco G; Magnani G; Pelloni I; Pinelli S; Pelà GM; Novarini A; Cabassi A; Montanari A
J Pharmacol Exp Ther; 2010 Sep; 334(3):911-6. PubMed ID: 20504911
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
20. Dynamic tissue perfusion assessment reflects associations between antihypertensive treatment and renal cortical perfusion in patients with chronic kidney disease and hypertension.
Lubas A; Kade G; Saracyn M; Niemczyk S; Dyrla P
Int Urol Nephrol; 2018 Mar; 50(3):509-516. PubMed ID: 29374813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
